We are committed to transforming cancer treatment by unleashing the full power of highly potent immunotherapies precisely in the tumors. Learn more about Xilio Therapeutics.
Location: United States, Massachusetts, Waltham
Employees: 51-200
Total raised: $195.5M
Founded date: 2020
Investors 12
Show more
Funding Rounds 2
| Date | Series | Amount | Investors |
| 25.02.2021 | Series C | $95M | - |
| 04.03.2020 | Series B | $100.5M | SV Health ... |
Mentions in press and media 19
| Date | Title | Description |
| 13.02.2025 | AbbVie signs heavily backloaded $2.1B Xilio biobucks pact in Big Pharma's latest T-cell engager deal | - |
| 28.03.2024 | Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing | - |
| 28.03.2024 | Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program | — Gilead Granted Exclusive License to Xilio’s Tumor-Activated IL-12 Program, Including XTX301, a Clinical-Stage IL-12 Molecule with Potential to Treat a Broad Range of Cancers — FOSTER CITY, Calif. & WALTHAM, Mass.--(BUSINESS WIRE)-- Gi... |
| 01.10.2021 | Solid tumor biotech Xilio Therapeutics files for a $100 million IPO | - |
| 25.02.2021 | Xilio Therapeutics Raises $95 Million in Series C Financing to Advance Potent Tumor-Selective Immuno-Oncology Pipeline | • Deal led by Rock Springs Capital and joined by Bain Capital Life Sciences, Deerfield Management, RA Capital Management and other investors |
| 25.02.2021 | Xilio Therapeutics Raises $95M in Series C | WALTHAM, MA, Xilio Therapeutics has closed a $95 million Series C financing led by Rock Springs Capital. >> Click here for more funding data on Xilio Therapeutics >> To export Xilio Therapeutics funding data to PDF and Excel... |
| 24.02.2021 | Xilio raises $95M to take twists on Yervoy and IL-2 into clinic | Xilio Therapeutics has raised $95 million to take IL-2 and CTLA-4 immunotherapies into clinical trials. The series C positions Xilio to provide early clinical validation of anti-cancer agents that are designed to remain inactive until they ... |
| 24.02.2021 | Xilio raises $95M to take twists on Yervoy and IL-2 into clinic | Xilio Therapeutics has raised $95 million to take IL-2 and CTLA-4 immunotherapies into clinical trials. The series C positions Xilio to provide early clinical validation of anti-cancer agents that are designed to remain inactive until they ... |
| 24.02.2021 | Xilio Therapeutics Raises $95 Million in Series C Financing to Advance Potent Tumor-Selective Immuno-Oncology Pipeline | February 24, 2021 06:00 AM Eastern Standard Time |
| 24.02.2021 | Xilio Therapeutics Raises $95 Million in Series C | WALTHAM, Mass.--(BUSINESS WIRE)--Xilio Therapeutics, a biotechnology company developing potent, tumor-selective immunotherapies for patients with cancer, today announced the successful closing of a $95 million Series C financing. Proceeds f... |
Show more